It is added because it addresses two specific and significant clinical problems that arise from GLP-1 receptor agonist therapy: nausea at treatment initiation and progressive B12 depletion over the course of long-term use
Helena St
Its commonly used to dilute or dissolve peptides and other medications before injection
Associate Professor, Academic Unit of General Practice and Community Health, Medical School, Australian National University, Canberra, ACT Margaret Kay MBBS(Hons), PhD, FRACGP, DipRACOG, Senior Lecturer, Discipline of General Practice, The University of Queensland, Herston, QLD Hoda Hanifi, BNurs, Postgrad Dip Mental Health Nursing, Clinical Nurse, Migrant Health Service, Adelaide, SA Gauri Giri, MNurs, BSc (Hons), Nurs, Community Health Worker, Migrant Health Service, Adelaide, SA Catherine Leahy BMus/BArts (Hons Psychology), PhD Medicine, Dip Counselling, Research Academic, Health Sciences, University of Adelaide, Adelaide, SA Michelle Lorimer BSc (Math & Comp Sci)(Hons), Senior Statistician, School of Population Health, University of Adelaide, Adelaide, SA Competing interests: None
Repairs Bone Tissue We just discussed how BPC-157 may help tissue repair
Key findings from receptor studies [2] : Long-term studies in -AR knockout mice showed no body weight reduction or lipolysis increases This verified the receptor pathways importance for sustained metabolic effects Acute experiments showed AOD9604 increased energy expenditure even in knockout mice Results suggest -AR expression enhances sensitivity but additional mechanisms exist beyond the direct receptor activation cAMP-PKA-HSL Pathway Activation The peptide triggers increases in intracellular cyclic AMP (cAMP) within adipocytes
